Current Opinion in Endocrinology & Diabetes and Obesity最新文献_第2页

Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia. 抑制血管生成素样蛋白3作为治疗高甘油三酯血症的靶点。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2025-12-17 DOI: 10.1097/MED.0000000000000950

Pablo Corral, Natalia Nardelli, Laura Schreier

{"title":"Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.","authors":"Pablo Corral, Natalia Nardelli, Laura Schreier","doi":"10.1097/MED.0000000000000950","DOIUrl":"10.1097/MED.0000000000000950","url":null,"abstract":"Purpose of review: To summarize recent advances in therapeutic strategies targeting angiopoietin-like protein 3 (ANGPTL3), a central regulator of triglyceride and remnant lipoprotein metabolism, and to discuss the potential of emerging pharmacologic approaches.Recent findings: Several pharmacologic approaches have demonstrated robust lipid-lowering efficacy through ANGPTL3 inhibition. Monoclonal antibodies (evinacumab, SHR-1918) and RNA-based therapies (vupanorsen, zodasiran, solbinsiran) effectively reduce triglycerides, apoprotein B (apoB)-containing lipoproteins, and nonhigh-density lipoprotein cholesterol. The newest and most promising innovation is CRISPR-mediated disruption of ANGPTL3 (CTX310).Summary: ANGPTL3 inhibition represents one of the most powerful current strategies for lowering triglyceride-rich lipoproteins and residual cardiovascular risk. While monoclonal antibodies and RNA-based drugs offer effective, repeat-dose therapies, in vivo CRISPR editing could enable a one-time, lifelong correction of hypertriglyceridemia and mixed dyslipidemia. The main challenge ahead lies in ensuring safety, scalability, and equitable access if long-term efficacy and tolerability are confirmed in phase 3 trials.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"77-83"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries. 高甘油三酯血症：来自新药临床试验和现实世界注册的最新信息。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2026-02-18 DOI: 10.1097/MED.0000000000000955

Mohamed Haseef, Stephen C H Li, Tobias Gaitt, Dick C Chan, Jing Pang, Gerald F Watts

{"title":"Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.","authors":"Mohamed Haseef, Stephen C H Li, Tobias Gaitt, Dick C Chan, Jing Pang, Gerald F Watts","doi":"10.1097/MED.0000000000000955","DOIUrl":"10.1097/MED.0000000000000955","url":null,"abstract":"Purpose of review: Hypertriglyceridemia (HTG) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis (AP). Early detection and treatment are important to prevent such complications. This review briefly outlines the etiology and novel treatments of HTG and recent findings from contemporary HTG registries.Recent findings: HTG is associated with an increased prevalence of cardiometabolic risk factors, including obesity, diabetes, and hepatic steatosis. Novel ribonucleic acid-based treatments for HTG have shown a substantial reduction in plasma triglycerides and a lower incidence of AP. A recent trial confirmed such benefit in patients with triglycerides >500 mg/dl (5.6 mmol/l), albeit with an increase in low-density lipoprotein-cholesterol, a reduction in remnant cholesterol and no change in apolipoprotein B. There is a need to harmonize the definitions of HTG and improve the care of individuals with severe HTG and familial chylomicronemia syndrome. New and evolving international registries are beginning to provide useful real-world data.Summary: Patient registries for HTG have provided valuable data for understanding the link between HTG and other cardiometabolic disorders; they can inform the planning of clinical services and the translation of the findings of new and future clinical trials of triglyceride-lowering therapies.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"66-76"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers and therapies to target endothelial dysfunction in type 2 diabetes: moving a step forward. 针对2型糖尿病内皮功能障碍的生物标志物和治疗：向前迈进了一步。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-10-29 DOI: 10.1097/MED.0000000000000933

Ying Jie Chee, Wann Jia Loh, Rinkoo Dalan

{"title":"Biomarkers and therapies to target endothelial dysfunction in type 2 diabetes: moving a step forward.","authors":"Ying Jie Chee, Wann Jia Loh, Rinkoo Dalan","doi":"10.1097/MED.0000000000000933","DOIUrl":"10.1097/MED.0000000000000933","url":null,"abstract":"Purpose of review: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM). Endothelial dysfunction is a precursor of atherosclerosis. This is a silent process that occurs over years. Focus on primary prevention to identify and target endothelial dysfunction early can slow down the atherosclerotic process and prevent ASCVD.Recent findings: Emerging blood-based methods include novel endothelial related biomarkers, such as endothelial specific extracellular vesicles, markers of endothelial regeneration and endothelial specific polygenic risk score. Physiology imaging-based method includes the flow-mediated dilation of the brachial artery, a noninvasive procedure that had gained attention for standardization in an international consensus guideline. Recognizing the role of endothelial function in ASCVD, studies are increasingly incorporating endothelial function biomarkers and FMD as surrogate markers of response. There is also emerging evidence on how nonpharmacological and pharmacological strategies improve endothelial function.Summary: Blood and imaging-based assessment of endothelial function is a promising area that can enhance early preventive efforts. Future studies to assess the incremental value of endothelial function assessment in contemporary longitudinal cohorts across diverse populations is necessary to identify the high-risk asymptomatic individuals who will benefit from intensive primary prevention.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"8-15"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The psychological dimension of obesity - an uncharted territory. 肥胖的心理层面——一个未知的领域。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-12-05 DOI: 10.1097/MED.0000000000000948

Stephen A Jiwanmall, Dheeraj Kattula

{"title":"The psychological dimension of obesity - an uncharted territory.","authors":"Stephen A Jiwanmall, Dheeraj Kattula","doi":"10.1097/MED.0000000000000948","DOIUrl":"10.1097/MED.0000000000000948","url":null,"abstract":"Purpose of review: To highlight the recent advancements in understanding the influence of psychological factors on the causation and management of obesity, which holds significance for clinical practice.Recent findings: This review explores developments in understanding psychological risk factors, sequelae, and treatments for obesity. Despite good evidence for psychological therapies in weight management, there are no standardized protocols for assessing patients requiring metabolic and bariatric surgery. Psychological therapies are synergistic with obesity medications.Summary: Obesity is a complex health issue with psychological dimensions. Stress, emotional dysregulation, and cognitive factors contribute to obesity. Stress's physiological impact on adipose tissue distribution and metabolic function, mediated by cortisol, demonstrates this interaction. Obesity leads to psychological consequences, including depression, low self-esteem, and reduced quality of life. The relationship between depression and obesity is modulated by demographic factors and biological mechanisms. Body composition reflects interactions between habits and cultural ideals, and medical models may increase stigma. Psychological interventions like cognitive-behavioral therapy and motivational interviewing effectively maintain weight loss. Psychological assessments before bariatric surgery are crucial for identifying mental health issues. This review highlights psychological dimensions in obesity prevention and treatment strategies.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"55-62"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolution of C-peptide's role in diabetes care. c肽在糖尿病治疗中的作用演变。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-12-08 DOI: 10.1097/MED.0000000000000947

Laura Briggs, Alexander Read, Sarah Darch, Emma L Williams, Wann Jia Loh, Julia S Kenkre

{"title":"The evolution of C-peptide's role in diabetes care.","authors":"Laura Briggs, Alexander Read, Sarah Darch, Emma L Williams, Wann Jia Loh, Julia S Kenkre","doi":"10.1097/MED.0000000000000947","DOIUrl":"10.1097/MED.0000000000000947","url":null,"abstract":"Purpose of review: Diabetes mellitus affects one in nine adults worldwide, with timely diagnosis and accurate classification being essential for patient management. C-peptide is an important biomarker in the diagnostic workup. As diabetes sub-typing and treatment options continue to evolve, this review will highlight the important aspects of C-peptide analysis and interpretation and additionally, evaluate its current and emerging clinical role.Recent findings: Several sample types and testing strategies such as fasting, random and stimulated C-peptide are available which are reviewed here. Random nonfasting C-peptide is convenient to perform in clinic and performs well compared to gold standard testing for classification of severe insulin deficiency and insulin dependence. C-peptide measurement may also be useful for classifying type 2 diabetes subtypes and in predicting response to treatment. Despite ongoing efforts towards standardization of C-peptide, variation still exists between analytical methods.Summary: This review summarizes recent literature relating to preanalytical, analytical and clinical aspects of C-peptide testing. Future research in this area may build on the role of C-peptide in predicting glycaemic control, clinical complications and response to pharmacotherapy.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"16-24"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of the PPAR system in diabetic cardiovascular risk and beyond. PPAR系统在糖尿病心血管风险及其他疾病中的作用。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-11-19 DOI: 10.1097/MED.0000000000000943

Massimiliano Ruscica, Chiara Macchi, Alberto Corsini, Cesare R Sirtori

{"title":"The role of the PPAR system in diabetic cardiovascular risk and beyond.","authors":"Massimiliano Ruscica, Chiara Macchi, Alberto Corsini, Cesare R Sirtori","doi":"10.1097/MED.0000000000000943","DOIUrl":"10.1097/MED.0000000000000943","url":null,"abstract":"Purpose of review: Peroxisome proliferator-activated receptors (PPARs) are transcription factors that regulate metabolic homeostasis and play a key role in the management of a number of metabolic disorders (e.g. diabetes and liver steatosis). This review aims to provide an overview on the impact of the three isoforms, PPAR-α, PPAR-β/δ and PPAR-γ, on diabetic-driven metabolic diseases.Recent findings: The lack of clinical benefit observed in the PROMINENT trial with pemafibrate (a selective PPAR-α agonist) has raised questions regarding the therapeutic potential of PPAR-α activation in the prevention of major cardiovascular events. Conversely, evidence suggests a possible therapeutic role in peripheral artery disease. To reduce the adverse effects occurring consequently to PPAR-γ activation, partial agonists or selective PPAR-γ modulators (SPPARγMs) have been developed. In the context of metabolic dysfunction associated steatohepatitis, pan-PPAR agonism appears necessary to achieve significant improvements in histological endpoints.Summary: These diversified effects, albeit with a limited risk of significant side effects, make PPAR agonists an area of growing interest and with an expanding range of potential applications.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjunctive diabetes therapies and cardiovascular protection in type 1 diabetes: tackling the challenging Tchaikovsky piece. 1型糖尿病的辅助糖尿病治疗和心血管保护：解决柴可夫斯基的挑战性作品。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-10-22 DOI: 10.1097/MED.0000000000000940

Wei Ting Wang, Wann Jia Loh

{"title":"Adjunctive diabetes therapies and cardiovascular protection in type 1 diabetes: tackling the challenging Tchaikovsky piece.","authors":"Wei Ting Wang, Wann Jia Loh","doi":"10.1097/MED.0000000000000940","DOIUrl":"10.1097/MED.0000000000000940","url":null,"abstract":"Purpose of review: This review aims to discuss the cardiometabolic-renal-glycaemic effects of adjunctive diabetes agents in the management of type 1 diabetes.Recent findings: Recent studies have investigated the effectiveness and safety of adjunctive diabetes agents such as metformin, SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 1 diabetes. A rising trend of use of diabetes technology, notably continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) devices, with improvement of glycaemic control, is observed. Questions arise whether these adjunctive diabetes agents and technologies confer cardiometabolic protective effects in patients with type 1 diabetes.Summary: The most widely studied adjunctive diabetes agent for type 1 diabetes is metformin. Meta-analyses suggest that metformin modestly improves glucose control, weight, lipid profile, and carotid intima-media thickness in patients with type 1 diabetes and mild obesity. SGLT2 inhibitors have been shown to modestly improve glycaemic control, weight, and blood pressure but are associated with increased risk of diabetic ketoacidosis in individuals with type 1 diabetes. The use of GLP-1 RA in type 1 diabetes with mild obesity provided modest HbA1c and weight reduction, but gastrointestinal side effects were common. The results of the ongoing phase 3 clinical trial of finerenone study in type 1 diabetes on chronic kidney disease progression are awaited. Observational studies suggest that CSII and CGM may also reduce cardiovascular events and hospitalizations in patients with type 1 diabetes.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"33-41"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145344133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and infertility: a double whammy. 肥胖和不孕：双重打击。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-11-27 DOI: 10.1097/MED.0000000000000944

Sairabanu Mohamed Rashid Sokwalla, Swafiya Busaidy, Gautam Das

{"title":"Obesity and infertility: a double whammy.","authors":"Sairabanu Mohamed Rashid Sokwalla, Swafiya Busaidy, Gautam Das","doi":"10.1097/MED.0000000000000944","DOIUrl":"10.1097/MED.0000000000000944","url":null,"abstract":"Purpose of review: Alongside its impact on cardio-metabolic parameters, obesity has been linked to infertility. This article aimed to provide a comprehensive review of the most current evidence linking male and female obesity and infertility.Recent findings: The risk of infertility affects both sexes: in males, excess adiposity alters the optimal functioning of the hypothalamic-pituitary-gonadal axis, affects function of the testicles and causes disruptions in spermatogenesis and sperm maturation whereas in females, obesity upsets the normal hormonal milieu which negatively impacts ovarian and uterine function leading to anovulation, menstrual irregularities, difficulties in development of embryo and implantation and recurrent miscarriages, especially in women with polycystic ovarian syndrome (PCOS) where hyperinsulinemia, hyperandrogenemia and other metabolic disruptions are involved.Summary: Numerous studies have established clear links between male and female obesity with infertility and to its pathophysiology and demographics. Evidence on treatment of obesity and impact on fertility outcomes is variable and needs further exploration.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"42-54"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145631173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can artificial intelligence and wearable technologies transform diabetes foot health? 人工智能和可穿戴技术能改变糖尿病足健康吗？

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-11-06 DOI: 10.1097/MED.0000000000000942

Wing May Kong, Farah Saif

{"title":"Can artificial intelligence and wearable technologies transform diabetes foot health?","authors":"Wing May Kong, Farah Saif","doi":"10.1097/MED.0000000000000942","DOIUrl":"10.1097/MED.0000000000000942","url":null,"abstract":"Purpose of review: Diabetes foot ulcers (DFUs) affect millions globally, and are a global health challenge, contributing significantly to morbidity, mortality, and healthcare costs. This review article critically evaluates advances in artificial intelligence and new technologies and their potential to transform diabetes foot complications.Recent findings: Artificial intelligence-based thermal and clinical image analysis offer the potential for early detection, remote diagnosis and monitoring and to mitigate disparities in specialist access. Incorporating novel pressure and temperature sensing, wearable technologies could enhance foot monitoring and enable personalized care and intervention. However, ethical challenges with artificial intelligence, including accountability, limited explainability, data security and equitable access will have to be addressed.Summary: Artificial intelligence and wearable technologies could herald a paradigm shift in diabetes foot health and research. However, these exciting tools are not yet ready for adoption in clinical practice. Larger, well funded clinical intervention studies and greater collaboration between clinicians, artificial intelligence scientists and product engineers, working in partnership with people with diabetes, is needed if these approaches are to fulfil their potential.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"25-32"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145631143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging concepts in the diagnosis and management of metabolically associated steatotic liver disease. 代谢相关脂肪变性肝病诊断和治疗的新概念

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2025-12-01 Epub Date: 2025-10-10 DOI: 10.1097/MED.0000000000000935

Sambit Das, Khushboo Agarwal, Nitin Kapoor, Om J Lakhani, Arundhati Das Gupta

{"title":"Emerging concepts in the diagnosis and management of metabolically associated steatotic liver disease.","authors":"Sambit Das, Khushboo Agarwal, Nitin Kapoor, Om J Lakhani, Arundhati Das Gupta","doi":"10.1097/MED.0000000000000935","DOIUrl":"10.1097/MED.0000000000000935","url":null,"abstract":"Purpose of review: Given the global rise of MASLD, which impacts approximately one-third of the population, there is a need for earlier diagnosis and effective treatment strategies to avoid long-term hepatic cardiovascular and renal complications. This review summarizes the recent advances in noninvasive diagnosis and new pharmacological agents approved for MASLD.Recent findings: The main step forward in diagnostics is a step away from invasive biopsy and emphasis on noninvasive methods including serum biomarkers (e.g. CK-18 and FGF21), imaging (e.g. MRI-PDFF and US-FLI), combination of the two and use of artificial intelligence and machine learning models, for early detection and risk stratification of MASLD and MASH. Multiomics approaches, such as metabolomics and lipidomics, reveal disease-specific signatures, and may help with phenotypic classification of MASLD. Personalized management for MASLD include gut microbiota modulation and point-of-care devices for rapid diagnosis. Novel therapies include THR β agonists, GLP-1/dual GLP-1/GIP agonists, FXR agonists and FGF analogues, which show promise in reducing hepatic fat and fibrosis.Summary: These findings enable earlier MASLD diagnosis and tailored interventions, improving clinical outcomes in primary care and resource-limited settings. Future research should focus on validating cost-effective tools, and developing combination therapies to address the multifaceted nature of MASLD.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"269-278"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0